Volume 3(1), 2023

Open Access

24-HJPV3(1)-2023 Review Article

THE ROLE OF COVID-19 ON ANTIBIOTICS RESISTANCE: A REVIEW-BASED STUDY

Sabiha Gul[1*], Tania Naveel[2], Zabab khan[2], Sabira Nazim Shah[3], Hafizullah[4]

[1]Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Via de Crecchio 7, 80138 Napoli (Italy).
[2]Department of Pharmacology, Faculty of Pharmacy, Jinnah University for Women, Karachi, Pakistan.
[3]Hospital Pharmacist, Agha Khan University Hospital, Karachi, Pakistan.
[4]Faculty of Pharmacy, Hamdard University, Karachi, Pakistan.

***Corresponding author:** sabihagul4@gmail.com

ABSTRACT

In this study, research is conducted with an aim to recognize the role played by the pandemic of Covid-19 in the resistance of antibacterial or antibiotics. Antibiotics resistance tends to happen when the bacteria or some certain microbes evolve from the instruments or mechanisms that provide protection to them against the influences of the antibiotics. As study provides understandings that infection of Covid-19 is caused by a virus SARS-CoV-2. The objective of the study explores the influences of antibiotics on infection caused by this virus and how this virus causes resistance in the use of antibiotics.

Keywords: Antibacterial, antibiotic resistance, covid-19, SARS-CoV-2.

INTRODUCTION

Antibiotic resistance is still considered a threat to the health of the public during the pandemic of Covid-19 **[1]**. The experts of the Centers of diseases control (CDC) are involved in monitoring the latent influences of Covid-19 on the local public of resistance and use of antibiotics **[2]**. Experts of the CDC are troubled and convinced that the Covid-19 could unfasten or undo much of the progress of the nation on the resistance of antibiotics specifically in the hospitals **[3]**. Investigation delivered information that the pandemic of Covid-19 can develop a perfect tempest or storm for the infections comprises with the antibiotic resistance in the settings of healthcare **[4]**. For instance, some individuals or patients suffering from the disease of Covid-19 might stop or stay at the healthcare centers and hospitals for a huge instance **[5]**. Healthcare centers and hospitals have also practiced and experienced shortages of staff **[6]**, a greater numeral of ill individuals to care for **[7]**, and problems and difficulties imposing practices for the control of infections **[8]**. Inappropriately or unfortunately, these loads on several systems of healthcare centers have developed it difficult to way healthcare-onset infections initially in the pandemic

[9]. The existing disease of Covid-19 has crossed every state or country **[10]**, providing huge disturbance in the worldwide economy and most significant consequences into the loss of millions of lives **[11]**. Since the initiation of the Covid-19, several of the focuses have been centered on the diagnosis and management of the disease of Covid-19 and the influences on the antibacterial and antimicrobial has been observed at a huge scale specifically at the healthcare centers and hospitals **[12]**. Covid-19 is a disease caused due to the SARS-CoV-2 *(Severe Acute Respiratory Syndrome Coronavirus-2)*, as such kind of antibiotics or antibacterial will not directly deliver influences on the virus (SARS-CoV-2).

Association of co-infections and secondary infections with Covid-19

It has been designated or demonstrated for an accountable period that the biological or viral respiratory contagions infection influenced patients to the infections of bacteria and that these co-infections comprise with the risky or worse results that either contamination or infection than on its own **[13]**. Yet, it is not certified that what certain roles super-infections or co-infections endure in the individuals suffering from the infection of Covid-19 **[14]**. Coronaviruses have been declared to be significant human pathogens and comparatively or relatively usual causes of both severe infections in the respiratory system of children and adults and both upper infections in the respiratory system of adults **[15]**. Unadorned or severe pneumonia has been comprised with the outbursts or outbreaks of the infections of coronavirus notable SARS (Severe acute syndrome in the respiratory system) **[16]** and MERS (Middle East Respiratory Syndrome). The initial studies and investigations associated with the pandemic of Covid-19 did not deliver any information on the existence of the secondary infections and co- infections **[17]**.

Antimicrobial stewardship

The intention or reason that it is much necessary to recognize whether the secondary infections and co-infections do happen in the patients of Covid-19 and whether this would lead to the justification of the requirements for the early empiric conduct through the antibiotics **[18]**. It is due to the risks and concerns of collations and adverse circumstances that may happen with the overuse and daily use of antibiotics **[19]**, with succeeding growth of resilient or resistant acquired in the hospitals and fungal and bacterial pathogens **[20]**, which are conflicting or contrary to the aims and principles of the program of antimicrobial stewardship. Several of the infected cases of pneumonia individuals during the pandemic of Covid-19 **[21]** comprised with the same radiological and clinical features that may develop it hard to make a difference from other usual bacterial, fungal or viral causes of pneumonia **[9]**.

Investigations have provided information that the pandemic of Covid-19 has had comprised with the necessary implications for the antimicrobial resistance, together with bad or good **[22]**. Several of the features or aspects that may positively influence the antimicrobial resistance include social distancing with the limits of contact among the individuals **[23]**, the

reference on washing hands regularly and wearing of the facemasks as well as the separation and isolation of infected cases along with following careful purification or sterilization of their atmosphere **[24]**.

The disadvantage or downside may be due to the overuse of antibacterial or antibiotics, if they are utilized on a routine basis, which is reported to the general **[25]**, as well as the utilization of the antimicrobials with the name of repurposed drugs for the treatment of infections of Covid-19 itself even in the absence of the co-infection **[26]**. On the huge investigation from the United States documented that initially empiric therapy through the utilization of the antibiotics was opted in more than fifty-five percent of individuals who were staying in the hospital or hospitalized due to the disease and infection of the Covid-19 , yet only more than three and a half percent of the patients had a certified communal-onset microbial or bacterial co-infections in the individuals with the infections of Covid-19 on their admission in hospital for more embattled or targeted early utilization of the antibiotics and to this end, it has been optional that procalcitonin **[27]**, in certain, may be considered as the useful biomarker **[17]**.

The investigation provided information that several of the efforts of the nation for the purpose to provide prevention to the spread of the coronavirus also delivered support in the rivalry against the antibacterial or antibiotic resistance **[28]**. These pains or efforts comprising with the investments of CDC in the control, prevention, **[29]** training, and surveillance of infection, and the personnel for the public health which includes **[30]**:

- Delivering support to the experts involved in the control and prevention of infection specifically while addressing the antibiotics and infections resistance **[14].**
- Delivering coronavirus testing and recognizing outbreaks of antibiotic-resistant through the AR Lab Network (Antibiotic Resistance Laboratory Network) of CDC in different fifty countries and distinct cities **[31]**.
- Development and imposition of the utilization of tools comprising antibiotics for the frontline entities **[32]**.
- Operating with the partners and providing support to the projects for the improvement in public and clinical health outcomes and control upsurging threats of the infectious diseases such as Covid-19 and antibiotic resistance **[15]**.

Control of healthcare infection is necessary to fight Covid-19 and antibiotic resistance.

Investigation and study provided information that the individuals hospitalized in the healthcare centers and hospitals due to a pathological or viral infection like flu (influenza) or Covid- 19 **[33]**, can also attain or get an infection that spread by any fungi or bacteria **[34]**. These are certainly referenced as secondary contaminations or infections **[35]**. The study also explored that during the Covid-19 pandemic within the year of 2020 demonstrated that, entire **[36]**, most hospitalized individuals suffering from the infection of Covid-19 are about as probable or likely to have secondary

contamination as hospitalized entities or individuals with the illness similar to influenza **[12]**.

The data attained through the investigations and researches demonstrated that the hospitalized individuals with the infection of Covid-19 were similarly to attain **[6]** these secondary fungi and bacterial infections during they were hospitalized in the healthcare centers **[37]**. On the contrary, hospitalized entities with an illness that was similar to influenza more usually attained secondary fungal and bacterial infections during they existed in the community before the hospitalization in the healthcare centers **[17]**.

The data tend to explore understandings that the patients suffering from the infection of Covid-19 may be more vulnerable to attaining secondary contamination while hospitalized **[38]**. Infections that tend to happen while in a healthcare center or hospital are more similar to be spread by the resistant germs **[39]**. The data also provided information that during the pandemic of Covid-19 in the year 2020 **[40]**, some germs caused several hospital-onset infections in the blood of patients from **[41]**, the reports that were obtained from such hospitals or healthcare centers **[42].** Reports also declared hospital-onset pulmonary aspergillosis **[37]**. It is considered as an infection caused by the fungus named Aspergillus **[43]**, which can be resistant with very few options of treatment. Scientists excluded that such kind of infection happened chiefly in the individuals with weakened systems of immunity or experienced any organ transplantation **[9]**.

Yet, in previous years and during the Covid-19 pandemic, it has been progressively reported as secondary and co-secondary respiratory infections like the Covid-19 **[44]**. CDC is operating with its partners for recognition of the individual patient and the facility factors of healthcare driving the progression of several infections **[45]** which are laying individuals suffering from the infection of Covid-19 at the huge risks for the fungal or bacterial secondary **[46]** infections that can be resilient or resistant to the drugs that designed certainly for their treatment **[22]**.

There have been several outbursts of antibiotic-resistant *Candi*da and *Acinetobacter* comprising the *C. auris* in the units of Covid-19 **[47]**. Scientists are doubtful or suspicious that control of infection gaps created due to the pressure of the pandemic may have prejudiced or influenced the development and spread of such microorganisms or germs **[48]** in the different healthcare centers and hospitals **[49]**. CDC and partners of the public health delivered responses **[50**] to more than twenty outbursts that spread by the germs in the treatment of Covid- 19 and the units of the observation **[51]**. The huge influences on the feast or blowout of the germs of antibiotic-resistant in an area are unusual **[14].**

Antibiotics utilize differs across the settings of healthcare.

Antibiotics are not considered efficacious certainly against the virus involved in the infection of Covid-19. It is because antibiotics do not involve in the treatment of the infections caused by the viruses

[52]. Antibiotics are involved in saving lives but at any instance **[53]**, antibiotics are utilized, they comprise the capability to cause side effects and lead to the resistance of the antibiotics **[54]**. In the healthcare centers and hospitals, antibiotics utilize progressed or increased for several certain antibacterial or antibiotics like ceftriaxone and azithromycin, which are usually utilized for the treatment of the infections of community- onset respiratory contaminations **[55].**

This utilization similarly tends to reflect the problems in differencing the Covid-19 from pneumonia that acquired through the community caused by certain bacteria when entities first reach for inpatient healthcare **[56]**. In the settings of outpatient, such as offices of the doctors, the utilization of antibiotics has experienced a drop necessarily **[57]**. This is similar because casualty hospitals or healthcare involved in the utilization of bacteria decreased during the Covid-19 pandemic **[58]**. Azithromycin recommendation was greater than the expectations **[59]**, specifically in the geographical regions with greater numerals of the cases of Covid-19 **[60].** This might be a likeness or reflection of its initial promotion as a probable therapy **[61]**, notwithstanding its inefficiency against the viruses, specifically the virus involved in the infection of Covid-19 **[62]**. In the homes that are used for nursing, the utilization of the antibiotics pointed with the variations during the Covid-19 pandemic but tends to remain lower entirely likened to the measurements before the pandemic **[63].**

In settings of the nursing homes, azithromycin recommending the remained raised through the October of the recent year. The numeral of the fungal and bacterial isolates and specimens tested and received in 2020 by the AR Lab Network of the center for control and prevention of diseases was about more than twenty percent less than the levels of 2019 **[64**]. It may be due to the facility of healthcare and staff for public health had to emphasize to the Covid-19 **[65]**. The seven regional labs of the AR Lab Network **[66]** delivered support to each other during the pandemic of Covid-19 to sustain the necessary national testing for the resistance of the antibiotics **[67].** For instance, several labs delivered an offer outside of their usual regions when others were defied or challenged by the shortages of supply or staff, and equipment of those labs was diverted to test the entities of the Covid-19 **[68]**. The investigation provided information testing for the resistance of antibiotics declined or slowed during the pandemic of Covid-19 **[69]**.

Environmental side effects comprising the injudicious utilization of antimicrobials during the pandemic of Covid-19

Investigation and researches provided information that utilization of the antimicrobials during the prevention and treatment of the infection of Covid-19 [76], caused by a certain virus (SARS-CoV-2) is increased at a huge scale **[70]**. The progression involved in the utilization of the antimicrobials can comprise the serious outcomes on the atmosphere or environment **[71]**. Antibiotics or antibacterial have had an accountable role

in the co-infections that are usually caused by the bacteria concerning the prevention and management of the Covid-19 **[72]**. Yet, previous information and evidence attained through investigation tends to provide suggestions that there have been imprudent or injudicious prescriptions associated with the use of antimicrobials **[24]**.

Furthermore, a huge number of the individuals is self-medicating with the antibiotics in a wrong or misguided attempt with an aim to protect themselves from the virus. Such kind of practice is specifically predominant in the development of communities **[73]**. Yet, usual soaps are efficacious at inactivation of the enclosed viruses, like the Covid-19 (SARS-CoV- 2) **[74]**, utilization of the antibacterial products comportment the biocides have progressed specifically during the pandemic of Covid-19 **[24]**. Existing techniques for wastewater treatment are not comprising with the capability to offer entire removal or rejection of the biocides of antibacterial **[75]**. These complexes and compounds can then accrue in distinct compartments of the environment thus, disrupting the operation and functions of the native microorganisms **[22]**.

These microorganisms or microbes are involved in the remediation of the environment and the biochemical cycling of certain elements **[76]**. Furthermore **[77]**, the existence of the elements of antibiotics in the environment can result in the stimulation of the resistance of antibiotics **[78]**. The growth of a policy for antimicrobial particularly required the solution of this certain problem **[22]**. Investments for the purpose to bring improvement in the structure of wastewater as the study provides understandings that awareness for the public is also necessary during the pandemic of Covid-19 **[78]**. Yet **[72**], the worldwide designed programs for monitoring and multidisciplinary associations are needed to consider the environmental influence of the Covid-19 pandemic **[55]**.

Role of the Pharmacists against the disease of Covid-19

As the studies explored that Covid-19 (Corona virus disease) is considered as the viral contamination or infection that influences the respiratory system **[9]**. The antiquity or history of the human corona viruses can be old-fashioned or dates to as initially as 1965 when the scientists of that era were comprised with the capability to do isolation of the viruses from the respiratory tract **[79]** of the humans who had agonized from the colds **[80]**. Covid-19 tends to be caused by SARS-CoV-2, that targets the human respiratory system [81]. Clinical appearances or manifestations of the SARS-CoV-2 comprising the dry cough, fever, shortness of the breath, headache, pressure in the chest or chest fever, sputum, vomiting, respiratory failure, diarrhea, sore throat, septic shock, organ failure, and confusion but such kind of appearances cannot be manifested until more than two to fourteen days after contact to the Covid-19 (SARS-CoV-2) **[82]**.

The antibiotics continue the bedrock of what is admired. Intensive care, immunosuppressive transplantations, and complex surgeries all would be not latent

if the infection could not dependably be measured or controlled **[83]**. In the year 2020 **[84]**, the medical network developed without any of the viral tests. The pandemic of influenza from the year of 1958 to 1959 involved the death of many but was ended by a combination of strain vaccination and burnout **[85]**. HIV took a forbidding toll but was hugely avoidable through the self-precautions and is managed by scientists, but the Covid-19 (SARS-CoV-2) has altered the dynamic, whether provisionally or permanently **[86]**.

CONCLUSION

Antibiotics reinforce or underpin the innovative medicine that has progressed expectancy of life, foremost to the social domains with large susceptible elderly inhabitants who have suffered excessively during the existing pandemic of Covid-19. Administrations have replied by limiting the interactions in the social domain, shuttering economics, and re- emphasizing healthcare. There are certain implications for the resistance of antibiotics both after and during the pandemic of Covid-19.

In the year 2020, a pandemic of Covid-19 harassed or stressed the relaxed stewardship of ICU, maybe promotion of the resistance. Counterpoised to this, most of the citizens killed due to this at home and entire healthcare centers and hospitals antibiotics utilization declined, reduction in the pressure of selection. Social distancing and restricted traveling potentially caused the reduction in importing of community and broadcast of the resistant bacteria through difficult information are lacking. The future relies on the vaccination now being organized. A clear progression of the vaccination should certify a summary return to the ordinariness and normality. The failure associated with the use of vaccination admired by the successful and extended non-pharmaceutical conquest or suppression may be directed towards the similar points, but only after a few postponements, and with the unlimited restrictions of traveling, and the maintenance is considered doubtful in the existing circumstances.

The information attained from investigations suggested that the Covid-19 will be managed and controlled, and that healthcare centers and hospitals will revert to the aspects of pre-202 with a huge accumulation of non-Covid-19 entities pending for the treatment. Clarification of this will upsurge the loads on working, nosocomial infections, stresses, resistance along with the utilization of the antibiotics.

REFERENCES

1. Murni, I.K., T. Duke, S. Kinney, A.J. Daley, and Y. Soenarto, *Reducing hospital-acquired infections and improving the rational use of antibiotics in a developing country: an effectiveness study.* Archives of disease in childhood, 2015. 100(5): p. 454-459.
2. Qutob, N. and F. Awartani, *Knowledge, attitudes and practices (KAP) towards COVID-19 among Palestinians during the COVID-19 outbreak: A cross-sectional survey.* Plos One, 2021. 16(1): p. e0244925.
3. Mudenda, S., *Letter to Editor: Coronavirus disease (COVID-19):*

a global health problem. Journal of Pharmaceutical Research Science & Technology [ISSN: 2583-3332], 2020. 4(1): p. 1-2.

4. Ruiz, J., *Enhanced antibiotic resistance as a collateral COVID-19 pandemic effect?* Journal of Hospital Infection, 2021. 107: p. 114-115.
5. Iwu, C.J., P. Jordan, I.F. Jaja, C.D. Iwu, and C.S. Wiysonge, *Treatment of COVID-19: implications for antimicrobial resistance in Africa.* The Pan African Medical Journal, 2020. 35(Suppl 2).
6. Mallah, N., D.A. Badro, A. Figueiras, and B. Takkouche, *Association of knowledge and beliefs with the misuse of antibiotics in parents: A study in Beirut (Lebanon).* Plos One, 2020. 15(7): p. e0232464.
7. Porretta, A.D., A. Baggiani, G. Arzilli, V. Casigliani, T. Mariotti, F. Mariottini, G. Scardina, D. Sironi, M. Totaro, and S. Barnini, *Increased risk of acquisition of New Delhi metallo-beta-lactamase-producing carbapenem-resistant Enterobacterales (NDM-CRE) among a cohort of COVID-19 patients in a teaching hospital in Tuscany, Italy.* Pathogens, 2020. 9(8): p. 635.
8. Nieuwlaat, R., L. Mbuagbaw, D. Mertz, L.L. Burrows, D.M. Bowdish, L. Moja, G.D. Wright, and H.J. Schünemann, *Coronavirus disease 2019 and antimicrobial resistance: parallel and interacting health emergencies.* Clinical Infectious Diseases, 2021. 72(9): p. 1657-1659.
9. Chang, C.T., M. Lee, J.C.Y. Lee, N.C.T. Lee, T.Y. Ng, A.A. Shafie, and K.S. Thong, *Public KAP towards COVID-19 and antibiotics resistance: a Malaysian survey of knowledge and awareness.* International Journal of Environmental Research and Public Health, 2021. 18(8): p. 3964.
10. Joo, S.H. and H. Choi, *Field grand challenge with emerging superbugs and the novel coronavirus (SARS-CoV-2) on plastics and in water.* Journal of environmental chemical engineering, 2021. 9(1): p. 104721.
11. Shah, S., V. Wordley, and W. Thompson, *How did COVID-19 impact on dental antibiotic prescribing across England?* British dental journal, 2020. 229(9): p. 601-604.
12. Farrell, J.M., C.Y. Zhao, K.M. Tarquinio, and S.P. Brown, *Causes and consequences of COVID-19-associated bacterial infections.* Frontiers in Microbiology, 2021. 12: p. 682571.
13. Al-Hanawi, M.K., K. Angawi, N. Alshareef, A.M. Qattan, H.Z. Helmy, Y. Abudawood, M. Alqurashi, W.M. Kattan, N.A. Kadasah, and G.C. Chirwa, *Knowledge, attitude and practice toward COVID-19 among the public in the Kingdom of Saudi Arabia: a cross-sectional study.* Frontiers in public health, 2020. 8:

p. 217.
14. Feldman, C. and R. Anderson, *The role of co-infections and secondary infections in patients with COVID-19.* Pneumonia, 2021. 13: p. 1-15.
15. Murray, A.K., *The novel coronavirus COVID-19 outbreak: global implications for antimicrobial resistance.* Frontiers in microbiology, 2020. 11: p. 1020.
16. Berendonk, T.U., C.M. Manaia, C. Merlin, D. Fatta-Kassinos, E. Cytryn, F. Walsh, H. Bürgmann, H. Sørum, M. Norström, and M.-N. Pons, *Tackling antibiotic resistance: the environmental framework.* Nature reviews microbiology, 2015. 13(5): p. 310-317.
17. Goff, D.A., D. Ashiru-Oredope, K.A. Cairns, K. Eljaaly, T.P. Gauthier, B.J. Langford, S.F. Mahmoud, A.P. Messina, U.C. Michael, and T. Saad, *Global contributions of pharmacists during the COVID-19 pandemic.* Journal of the American College of Clinical Pharmacy, 2020. 3(8): p. 1480-1492.
18. Bengoechea, J.A. and C.G. Bamford, *SARS-CoV-2, bacterial co-infections, and AMR: the deadly trio in COVID-19?* EMBO molecular medicine, 2020. 12(7): p. e12560.
19. Tria, J.Z., *The COVID-19 pandemic through the lens of education in the Philippines: The new normal.* International Journal of Pedagogical Development and Lifelong Learning, 2020. 1(1): p. 2-4.
20. Amaran, S., A.Z.M. Kamaruzaman, N.Y.M. Esa, and Z. Sulaiman, *Malaysia healthcare early response in combatting COVID-19 pandemic in 2020.* Korean journal of family medicine, 2021. 42(6): p. 425.
21. He, D., S. Zhao, Q. Lin, Z. Zhuang, P. Cao, M.H. Wang, and L. Yang, *The relative transmissibility of asymptomatic COVID-19 infections among close contacts.* International Journal of Infectious Diseases, 2020. 94: p. 145-147.
22. Rawson, T.M., L.S. Moore, N. Zhu, N. Ranganathan, K. Skolimowska, M. Gilchrist, G. Satta, G. Cooke, and A. Holmes, *Bacterial and fungal coinfection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing.* Clinical infectious diseases, 2020. 71(9): p. 2459-2468.
23. Chen, N., M. Zhou, X. Dong, J. Qu, F. Gong, Y. Han, Y. Qiu, J. Wang, Y. Liu, and Y. Wei, *Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.* The lancet, 2020. 395(10223): p. 507-513.
24. Usman, M., M. Farooq, and K. Hanna, *Environmental side effects of the injudicious use of antimicrobials in the era of COVID-19.* Science of the Total Environment, 2020. 745: p. 141053.

25. Siemieniuk, R.A., J.J. Bartoszko, D. Zeraatkar, E. Kum, A. Qasim, J.P.D. Martinez, A. Izcovich, B. Rochwerg, F. Lamontagne, and M.A. Han, *Drug treatments for covid-19: living systematic review and network meta-analysis.* Bmj, 2020. 370.
26. Gudapuri, L., *Cross-resistance between antiseptic agents and antimicrobial agents.* Biom Biostat Int J, 2018. 7(5): p. 429-430.
27. Zhang, D., H. Ling, X. Huang, J. Li, W. Li, C. Yi, T. Zhang, Y. Jiang, Y. He, and S. Deng, *Potential spreading risks and disinfection challenges of medical wastewater by the presence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) viral RNA in septic tanks of Fangcang Hospital.* Science of the Total Environment, 2020. 741: p. 140445.
28. Hernando-Amado, S., T.M. Coque, F. Baquero, and J.L. Martínez, *Antibiotic resistance: Moving from individual health norms to social norms in one health and global health.* Frontiers in Microbiology, 2020. 11: p. 1914.
29. Zhong, B.-L., W. Luo, H.-M. Li, Q.-Q. Zhang, X.-G. Liu, W.-T. Li, and Y. Li, *Knowledge, attitudes, and practices towards COVID-19 among Chinese residents during the rapid rise period of the COVID-19 outbreak: a quick online cross-sectional survey.* International journal of biological sciences, 2020. 16(10): p. 1745.
30. Cantón, R., D. Gijón, and P. Ruiz-Garbajosa, *Antimicrobial resistance in ICUs: an update in the light of the COVID-19 pandemic.* Current opinion in critical care, 2020. 26(5): p. 433-441.
31. Mirzaei, R., P. Goodarzi, M. Asadi, A. Soltani, H.A.A. Aljanabi, A.S. Jeda, S. Dashtbin, S. Jalalifar, R. Mohammadzadeh, and A. Teimoori, *Bacterial co-infections with SARS-CoV-2.* IUBMB life, 2020. 72(10): p. 2097-2111.
32. Perez, S., G.K. Innes, M.S. Walters, J. Mehr, J. Arias, R. Greeley, and D. Chew, *Increase in hospital-acquired carbapenem-resistant Acinetobacter baumannii infection and colonization in an acute care hospital during a surge in COVID-19 admissions—New Jersey, February–July 2020.* Morbidity and Mortality Weekly Report, 2020. 69(48): p. 1827.
33. Fernández, L., M.D. Cima-Cabal, A.C. Duarte, A. Rodriguez, P. García, and M.d.M. García-Suárez, *Developing diagnostic and therapeutic approaches to bacterial infections for a new era: implications of globalization.* Antibiotics, 2020. 9(12): p. 916.
34. Petersen, E., M. Koopmans, U. Go, D.H. Hamer, N. Petrosillo, F. Castelli, M. Storgaard, S. Al Khalili, and L. Simonsen, *Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics.* The Lancet infectious diseases, 2020. 20(9): p. e238-

e244.
35. Elengoe, A., *COVID-19 outbreak in Malaysia.* Osong public health and research perspectives, 2020. 11(3): p. 93.
36. MacIntyre, C.R. and C.M. Bui, *Pandemics, public health emergencies and antimicrobial resistance-putting the threat in an epidemiologic and risk analysis context.* Archives of Public Health, 2017. 75(1): p. 1-6.
37. Langford, B.J., M. So, S. Raybardhan, V. Leung, D. Westwood, D.R. MacFadden, J.-P.R. Soucy, and N. Daneman, *Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis.* Clinical microbiology and infection, 2020. 26(12): p. 1622-1629.
38. Organization, W.H., *Living guidance for clinical management of COVID-19: living guidance, 23 November 2021*. 2021, World Health Organization.
39. Collignon, P. and J.J. Beggs, *CON: COVID-19 will not result in increased antimicrobial resistance prevalence.* JAC-antimicrobial Resistance, 2020. 2(3): p. dlaa051.
40. Lau, L.L., N. Hung, D.J. Go, J. Ferma, M. Choi, W. Dodd, and X. Wei, *Knowledge, attitudes and practices of COVID-19 among income-poor households in the Philippines: A cross-sectional study*. Journal of global health, 2020. 10(1).
41. Jahangir, M.A., A. Muheem, and M.F. Rizvi, *Coronavirus (COVID-19): history, current knowledge and pipeline medications.* Journal of Pharmaceutical Research Science & Technology [ISSN: 2583-3332], 2020. 4(1): p. 1-9.
42. *WHO. detail/antimicrobial-resistance. 27 July];* . 2017; Available from: Available from: https://www.who.int/news-room/q-a.
43. Choo, S.J., C.T. Chang, J.C.Y. Lee, V. Munisamy, C.K. Tan, J.D. Raj, R.I.M. Taib, K.S. Thong, and A.A. Shafie, *A cross-sectional study on public belief, knowledge and practice towards antibiotic use in the state of Perak, Malaysia.* The Journal of Infection in Developing Countries, 2018. 12(11): p. 960-969.
44. Nasir, M., A. Chowdhury, and T. Zahan, *Self-medication during COVID-19 outbreak: a cross sectional online survey in Dhaka city.* Int J Basic Clin Pharmacol, 2020. 9(9): p. 1325-1330.
45. Yam, E.L.Y., *COVID-19 will further exacerbate global antimicrobial resistance.* Journal of travel medicine, 2020. 27(6): p. taaa098.
46. Guan, W.-j., W.-h. Liang, Y. Zhao, H.-r. Liang, Z.-s. Chen, Y.-m. Li, X.-q. Liu, R.-c. Chen, C.-l. Tang, and T. Wang, *Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis.* European respiratory journal, 2020. 55(5).
47. Arastehfar, A., A. Carvalho, M.H.

Nguyen, M.T. Hedayati, M.G. Netea, D.S. Perlin, and M. Hoenigl, *COVID-19-associated candidiasis (CAC): an underestimated complication in the absence of immunological predispositions?* Journal of fungi, 2020. 6(4): p. 211.

48. Thomas, R., H. Greenwood, Z.A. Michaleff, E. Abukmail, T.C. Hoffmann, K. McCaffery, L. Hardiman, and P. Glasziou, *Examining Australian's beliefs, misconceptions and sources of information for COVID-19: a national online survey.* BMJ open, 2021. 11(2): p. e043421.
49. Godman, B., M. Haque, S. Islam, S. Iqbal, U.L. Urmi, Z.M. Kamal, S.A. Shuvo, A. Rahman, M. Kamal, and M. Haque, *Rapid assessment of price instability and paucity of medicines and protection for COVID-19 across Asia: findings and public health implications for the future.* Frontiers in public health, 2020. 8: p. 585832.
50. Chu, D.K., E.A. Akl, S. Duda, K. Solo, S. Yaacoub, H.J. Schünemann, A. El-Harakeh, A. Bognanni, T. Lotfi, and M. Loeb, *Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis.* The lancet, 2020. 395(10242): p. 1973-1987.
51. Cilloni, L., H. Fu, J.F. Vesga, D. Dowdy, C. Pretorius, S. Ahmedov, S.A. Nair, A. Mosneaga, E. Masini, and S. Sahu, *The potential impact of the COVID-19 pandemic on the tuberculosis epidemic a modelling analysis.* EClinicalMedicine, 2020. 28.
52. Holubar, M., *Antimicrobial resistance: a global public health emergency further exacerbated by international travel*. 2020, Oxford University Press. p. taz095.
53. Ab Halim, N.A.A., C.-T. Chang, H.K. Chan, M.A. Hassali, and A. Nouri, *Knowledge and attitudes concerning antibiotic use and resistance among the public in Pulau Pinang, Malaysia.* The Malaysian journal of medical sciences: MJMS, 2018. 25(6): p. 141.
54. Huynh, G., M.Q. Nguyen, T.T. Tran, V.T. Nguyen, T.V. Nguyen, T.H.T. Do, P.H.N. Nguyen, T.H.Y. Phan, T.T. Vu, and T.N.H. Nguyen, *Knowledge, attitude, and practices regarding COVID-19 among chronic illness patients at outpatient departments in Ho Chi Minh City, Vietnam.* Risk management and healthcare policy, 2020: p. 1571-1578.
55. Shalev, D. and P.A. Shapiro, *Epidemic psychiatry: The opportunities and challenges of COVID-19.* General Hospital Psychiatry, 2020. 64: p. 68-71.
56. Gwenzi, W., *Leaving no stone unturned in light of the COVID-19 faecal-oral hypothesis? A water, sanitation and hygiene (WASH) perspective targeting low-income*

countries. Science of the Total Environment, 2021. 753: p. 141751.

57. Getahun, H., I. Smith, K. Trivedi, S. Paulin, and H.H. Balkhy, *Tackling antimicrobial resistance in the COVID-19 pandemic.* Bulletin of the World Health Organization, 2020. 98(7): p. 442.
58. Monnet, D.L. and S. Harbarth, *Will coronavirus disease (COVID-19) have an impact on antimicrobial resistance?* Eurosurveillance, 2020. 25(45): p. 2001886.
59. Wake, A.D., *Knowledge, attitude, practice, and associated factors regarding the novel coronavirus disease 2019 (COVID-19) pandemic.* Infection and drug resistance, 2020: p. 3817-3832.
60. Shahab, M.S., S.S. Imam, and M.A. Jahangir, *A review on the contemporary status of mutating coronavirus and comparative literature study of current COVID-19 vaccines.* Journal of Pharmaceutical Research Science & Technology [ISSN: 2583-3332], 2021. 5(1): p. 1-19.
61. Ray, K.N., Z. Shi, C.A. Gidengil, S.J. Poon, L. Uscher-Pines, and A. Mehrotra, *Antibiotic prescribing during pediatric direct-to-consumer telemedicine visits.* Pediatrics, 2019. 143(5).
62. Rossato, L., F.J. Negrão, and S. Simionatto, *Could the COVID-19 pandemic aggravate antimicrobial resistance?* American journal of infection control, 2020. 48(9): p. 1129-1130.
63. Barrios, J.M., E. Benmelech, Y.V. Hochberg, P. Sapienza, and L. Zingales, *Civic capital and social distancing during the Covid-19 pandemic☆.* Journal of public economics, 2021. 193: p. 104310.
64. Guerrero-Latorre, L., I. Ballesteros, I. Villacrés-Granda, M.G. Granda, B. Freire-Paspuel, and B. Ríos-Touma, *SARS-CoV-2 in river water: Implications in low sanitation countries.* Science of the Total environment, 2020. 743: p. 140832.
65. Zhang, Y., J. Lu, J. Wu, J. Wang, and Y. Luo, *Potential risks of microplastics combined with superbugs: Enrichment of antibiotic resistant bacteria on the surface of microplastics in mariculture system.* Ecotoxicology and environmental safety, 2020. 187: p. 109852.
66. Azlan, A.A., M.R. Hamzah, T.J. Sern, S.H. Ayub, and E. Mohamad, *Public knowledge, attitudes and practices towards COVID-19: A cross-sectional study in Malaysia.* Plos One, 2020. 15(5): p. e0233668.
67. Sahoo, B.P. and A.B. Patel, *Social stigma in time of COVID-19 pandemic: evidence from India.* International Journal of Sociology and Social Policy, 2021. 41(11/12): p. 1170-1182.
68. Haque, T., K.M. Hossain, M.M.R. Bhuiyan, S.A. Ananna, M.A. Hussain, M.R. Islam, A. Ahmed, and M.M. Rahman, *Knowledge, attitude and practices (KAP)*

towards COVID-19 and assessment of risks of infection by SARS-CoV-2 among the Bangladeshi population: An online cross sectional survey. 2020.

69. Calderón-Parra, J., A. Muiño-Miguez, A.D. Bendala-Estrada, A. Ramos-Martínez, E. Muñez-Rubio, E. Fernández Carracedo, J. Tejada Montes, M. Rubio-Rivas, F. Arnalich-Fernandez, and J.L. Beato Pérez, *Inappropriate antibiotic use in the COVID-19 era: Factors associated with inappropriate prescribing and secondary complications. Analysis of the registry SEMI-COVID.* Plos One, 2021. 16(5): p. e0251340.
70. Afzal, M.S., A. Khan, U.U.R. Qureshi, S. Saleem, M.A.N. Saqib, R.M.K. Shabbir, M. Naveed, M. Jabbar, S. Zahoor, and H. Ahmed, *Community-based assessment of knowledge, attitude, practices and risk factors regarding COVID-19 among Pakistanis residents during a recent outbreak: a cross-sectional survey.* Journal of community health, 2021. 46: p. 476-486.
71. Gomez-Simmonds, A., M.K. Annavajhala, T.H. McConville, D.E. Dietz, S.M. Shoucri, J.C. Laracy, F.D. Rozenberg, B. Nelson, W.G. Greendyke, and E.Y. Furuya, *Carbapenemase-producing Enterobacterales causing secondary infections during the COVID-19 crisis at a New York City hospital.* Journal of Antimicrobial Chemotherapy, 2021. 76(2): p. 380-384.
72. Chowdhary, A. and A. Sharma, *The lurking scourge of multidrug resistant Candida auris in times of COVID-19 pandemic.* Journal of global antimicrobial resistance, 2020. 22: p. 175.
73. Jain, V.K., K.P. Iyengar, D.A. Samy, and R. Vaishya, *Tuberculosis in the era of COVID-19 in India.* Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 2020. 14(5): p. 1439-1443.
74. McQuaid, C.F., N. McCreesh, J.M. Read, T. Sumner, R.M. Houben, R.G. White, R.C. Harris, and C.C.-W. Group, *The potential impact of COVID-19-related disruption on tuberculosis burden.* European respiratory journal, 2020. 56(2).
75. Al Ahdab, S., *A cross-sectional survey of knowledge, attitude and practice (KAP) towards COVID-19 pandemic among the Syrian residents.* BMC public health, 2021. 21: p. 1-7.
76. Fattorini, L., R. Creti, C. Palma, and A. Pantosti, *Bacterial coinfections in COVID-19: an underestimated adversary.* Annali dell'Istituto superiore di sanita, 2020. 56(3): p. 359-364.
77. Strathdee, S.A., S.C. Davies, and J.R. Marcelin, *Confronting antimicrobial resistance beyond the COVID-19 pandemic and the 2020 US election.* The Lancet, 2020. 396(10257): p. 1050-1053.
78. Arshad, A.R., I. Bashir, A. Tariq, F. Ijaz, R.K. Aftab, and O. Farooq,

A population based study on the healthcare seeking behaviour during the COVID-19 outbreak. Discoveries Reports, 2020. 3: p. e14.

79. Morens, D.M. and A.S. Fauci, *Emerging pandemic diseases: how we got to COVID-19.* Cell, 2020. 182(5): p. 1077-1092.
80. Kochi, A., B. Vareldzis, and K. Styblo, *Multidrug-resistant tuberculosis and its control.* Research in microbiology, 1993. 144(2): p. 104-110.
81. Rezasoltani, S., A. Yadegar, B. Hatami, H. Asadzadeh Aghdaei, and M.R. Zali, *Antimicrobial resistance as a hidden menace lurking behind the COVID-19 outbreak: the global impacts of too much hygiene on AMR.* Frontiers in microbiology, 2020. 11: p. 590683.
82. Sabin, N.S., A.S. Calliope, S.V. Simpson, H. Arima, H. Ito, T. Nishimura, and T. Yamamoto, *Implications of human activities for (re) emerging infectious diseases, including COVID-19.* Journal of physiological anthropology, 2020. 39(1): p. 1-12.
83. Goncalves Mendes Neto, A., K.B. Lo, A. Wattoo, G. Salacup, J. Pelayo, R. DeJoy III, R. Bhargav, F. Gul, E. Peterson, and J. Albano, *Bacterial infections and patterns of antibiotic use in patients with COVID-19.* Journal of medical virology, 2021. 93(3): p. 1489-1495.
84. Rhouma, M., M. Tessier, C. Aenishaenslin, P. Sanders, and H. Carabin, *Should the increased awareness of the One Health approach brought by the COVID-19 pandemic be used to further tackle the challenge of antimicrobial resistance?* Antibiotics, 2021. 10(4): p. 464.
85. Marimuthu, Y., B. Nagappa, N. Sharma, S. Basu, and K.K. Chopra, *COVID-19 and tuberculosis: A mathematical model based forecasting in Delhi, India.* Indian Journal of Tuberculosis, 2020. 67(2): p. 177-181.
86. Phiri, M.N., M. Banda, S. Mudenda, M. Ngazimbi, J. Hangoma, W. Mufwambi, R.K. Mutati, and L.T. Muungo, *Coronavirus Disease 2019 (COVID-19): the role of pharmacists in the Fight against COVID-19 Pandemic.* Journal of Pharmaceutical Research Science & Technology [ISSN: 2583-3332], 2020. 4(1): p. 1-3.